JP6621252B2 - 治療耐性がんに対する治療耐性低減剤 - Google Patents

治療耐性がんに対する治療耐性低減剤 Download PDF

Info

Publication number
JP6621252B2
JP6621252B2 JP2015122399A JP2015122399A JP6621252B2 JP 6621252 B2 JP6621252 B2 JP 6621252B2 JP 2015122399 A JP2015122399 A JP 2015122399A JP 2015122399 A JP2015122399 A JP 2015122399A JP 6621252 B2 JP6621252 B2 JP 6621252B2
Authority
JP
Japan
Prior art keywords
cells
csf
cancer
treatment
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015122399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017007956A5 (cg-RX-API-DMAC7.html
JP2017007956A (ja
Inventor
研一郎 清野
研一郎 清野
ムハンマド バグダーディー
ムハンマド バグダーディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Priority to JP2015122399A priority Critical patent/JP6621252B2/ja
Priority to US15/736,203 priority patent/US20180193453A1/en
Priority to PCT/JP2016/067906 priority patent/WO2016204216A1/ja
Priority to EP16811690.3A priority patent/EP3311840B1/en
Publication of JP2017007956A publication Critical patent/JP2017007956A/ja
Publication of JP2017007956A5 publication Critical patent/JP2017007956A5/ja
Application granted granted Critical
Publication of JP6621252B2 publication Critical patent/JP6621252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2015122399A 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤 Active JP6621252B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2015122399A JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤
US15/736,203 US20180193453A1 (en) 2015-06-17 2016-06-16 Treatment-resistance reducing agent for treatment-resistant cancer
PCT/JP2016/067906 WO2016204216A1 (ja) 2015-06-17 2016-06-16 治療耐性がんに対する治療耐性低減剤
EP16811690.3A EP3311840B1 (en) 2015-06-17 2016-06-16 Treatment-resistance reducing agent for treatment-resistant cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015122399A JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤

Publications (3)

Publication Number Publication Date
JP2017007956A JP2017007956A (ja) 2017-01-12
JP2017007956A5 JP2017007956A5 (cg-RX-API-DMAC7.html) 2018-08-02
JP6621252B2 true JP6621252B2 (ja) 2019-12-18

Family

ID=57545648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015122399A Active JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤

Country Status (4)

Country Link
US (1) US20180193453A1 (cg-RX-API-DMAC7.html)
EP (1) EP3311840B1 (cg-RX-API-DMAC7.html)
JP (1) JP6621252B2 (cg-RX-API-DMAC7.html)
WO (1) WO2016204216A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356317B1 (ja) * 2017-06-05 2018-07-11 国立大学法人北海道大学 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び／又は治療のための医薬
WO2020027217A1 (ja) * 2018-07-31 2020-02-06 国立大学法人北海道大学 がんの治療及び／又は予防のための医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CA2797399C (en) * 2010-05-04 2021-03-02 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
ES2618828T3 (es) * 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
CN104093740B (zh) * 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
JP6827928B2 (ja) * 2014-12-19 2021-02-10 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
TWI725966B (zh) * 2015-04-13 2021-05-01 戊瑞治療有限公司 癌症組合療法

Also Published As

Publication number Publication date
EP3311840A1 (en) 2018-04-25
US20180193453A1 (en) 2018-07-12
JP2017007956A (ja) 2017-01-12
EP3311840A4 (en) 2019-02-27
WO2016204216A1 (ja) 2016-12-22
EP3311840B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
JP7461449B2 (ja) 治療用ｒｎａ
JP7223055B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
CN110248645B (zh) 基于外来体的抗癌剂
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP2023053087A (ja) メモリー機能を有するｔ細胞又はｂ細胞の増強剤、悪性腫瘍再発抑制剤、及びｔ細胞又はｂ細胞にメモリー機能を誘導する誘導剤
JP2022092001A (ja) 樹状細胞免疫療法
WO2016189532A1 (en) Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
US11788093B2 (en) Chimeric antigen receptor t-cells expressing interleukin-8 receptor
CN108472317A (zh) 修饰免疫细胞及其用途
JP2020524141A (ja) がんを処置するための方法および組成物
US20180128833A1 (en) Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto
WO2018039332A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
Sheng et al. Antiangiogenic treatment facilitates the abscopal effect of radiation therapy combined with anti-pd-1 in hepatocellular carcinoma
JP6621252B2 (ja) 治療耐性がんに対する治療耐性低減剤
US20190269729A1 (en) Modified natural killer cells for the treatment of cancer
US20250381248A1 (en) Methods of treating a tumor
CN107326027A (zh) 一种rna嵌合体及其用途
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
US20250179166A1 (en) Treatment of brain metastasis
Ellert-Miklaszewska et al. Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcome
JP2019131505A (ja) 抗がん剤
Ausejo-Mauleón TIM-3 blockade as a therapeutic approach for diffuse intrinsic pontine glioma
US20230257713A1 (en) Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
Dastmalchi et al. IMMU-57. STRATEGY TO ENHANCE DC MIGRATION FOR INCREASED EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191119

R150 Certificate of patent or registration of utility model

Ref document number: 6621252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250